These findings provide a compelling rationale for exploration of IMPDH2 inhibitors such as AVN944 in the context of cancer treatment, setting the stage for their evaluation in clinical trials aimed at improving outcomes for patients with malignancies characterized by high IMPDH2 activity. The gene discussed is IMPDH2; the disease is cancer.